Boston Scientific Receives FDA Approval Of Spinal Cord Stimulation Therapy For People Living With Diabetic Peripheral Neuropathy
Portfolio Pulse from Bill Haddad
Boston Scientific has received FDA approval for its Spinal Cord Stimulation therapy for people living with Diabetic Peripheral Neuropathy. This approval could potentially open up a new market for the company's products.
October 11, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's FDA approval for its Spinal Cord Stimulation therapy could potentially boost its revenues as it opens up a new market.
The FDA approval of Boston Scientific's Spinal Cord Stimulation therapy for Diabetic Peripheral Neuropathy could potentially increase the company's revenues as it opens up a new market for its products. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100